Detalhe da pesquisa
1.
Immunometabolic Status of COVID-19 Cancer Patients.
Physiol Rev
; 100(4): 1839-1850, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32721181
2.
Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review.
Ann Oncol
; 35(1): 29-65, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37879443
3.
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671).
Ann Oncol
; 2024 Jun 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38857846
4.
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.
Ann Oncol
; 32(7): 881-895, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33894335
5.
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus.
Ann Oncol
; 31(10): 1320-1335, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32745693
6.
Is impaired response to PD-1 blockers of high serum PD-1 patients related to immune complexes?
Ann Oncol
; 32(6): 814-816, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33684461
7.
The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate.
Ann Oncol
; 32(5): 579-581, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33582237
8.
Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors.
Ann Oncol
; 26(5): 838-847, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25411417
9.
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.
Ann Oncol
; 26(10): 2079-84, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26209642
10.
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).
Ann Oncol
; 30(2): 161-165, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30624547
11.
Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R.
ESMO Open
; 9(6): 103464, 2024 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38833971
12.
Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey.
ESMO Open
; 8(2): 100781, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36842299
13.
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.
ESMO Open
; 7(2): 100408, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35279527
14.
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers.
ESMO Open
; 7(6): 100645, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36455507
15.
Correction to Lancet Oncol 2015; 16: 747. EGFR mutations and EGFR tyrosine kinase inhibitors.
Lancet Oncol
; 16(7): e313, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26149882
16.
Social distress among medical oncologists and other healthcare professionals during the first wave of COVID-19 pandemic in Italy.
ESMO Open
; 6(2): 100053, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33601297
17.
Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy.
ESMO Open
; 6(1): 100034, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33422766
18.
Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey.
ESMO Open
; 6(3): 100131, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34144778
19.
Female leadership in oncology-has progress stalled? Data from the ESMO W4O authorship and monitoring studies.
ESMO Open
; 6(6): 100281, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34924143
20.
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out.
Cancer Treat Rev
; 75: 39-51, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30954906